Back to top
more

Achilles Therapeutics (ACHL)

(Delayed Data from NSDQ)

$0.76 USD

0.76
382,132

-0.01 (-1.86%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.75 -0.01 (-1.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Acadia Healthcare (ACHC) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move

by Zacks Equity Research

Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.

Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?

by Zacks Equity Research

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.

Waters (WAT) Walk-Up Solutions Boost Bioprocess Development

by Zacks Equity Research

Waters (WAT) launches new bioprocess walk-up solutions, automating sample prep and analysis from any bioreactor.

Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.

Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.

Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock

by Zacks Equity Research

Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe

by Zacks Equity Research

Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.

Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion

by Zacks Equity Research

The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.

Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy

by Zacks Equity Research

Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.

Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why

by Zacks Equity Research

Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.

Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why

by Zacks Equity Research

Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.

IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study

by Zacks Equity Research

IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.

Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication

by Zacks Equity Research

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why

by Zacks Equity Research

Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104

by Zacks Equity Research

Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.

Sanofi (SNY) Gets FDA Nod for Rare Disease Drug Xenpozyme

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.

Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

by Zacks Equity Research

The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.

Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study

by Zacks Equity Research

Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.

Deciphera (DCPH) Thrives on Qinlock, Overdependence a Concern

by Zacks Equity Research

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.

    Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why

    by Zacks Equity Research

    Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.

    Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why

    by Zacks Equity Research

    Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.